US › Healthcare

Cocrystal Pharma Inc (COCP)

US · Healthcare · Biotechnology

$0.98+4.28%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$225,000

Net profit

$-2.3M

Profit YoY

+0.1%

EPS

$-0.17

EPS estimate

$-0.15

Net margin

-1,021.8%

EPS came in at -0.17 against a street estimate of -0.15 — a miss of 13.3%.

Key statistics

Market cap

$12.0M

Forward P/E

0.0

P/B

3.12

Book value

$0.30

EPS (TTM)

$-0.67

52-week high

$2.19

52-week low

$0.76

50-day MA

$1.02

200-day MA

$1.09

Beta

1.41

Analyst view

Analysts rate Cocrystal Pharma Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $9.00.

Shareholding

Insiders

30.73%

Institutions

5.26%

Largest institutional holders

Fund	Stake
Vanguard Group Inc	1.91%
Vanguard Capital Management, LLC	1.74%
Renaissance Technologies Corp	0.90%
Geode Capital Management, LLC	0.65%
BlackRock Inc	0.53%
T3 Companies, LLC	0.37%
XTX Topco Ltd	0.26%
Neuberger Berman Group LLC	0.23%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cocrystal Pharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.